Dr. Lemeng Zhang 张乐蒙
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of chest malignancies including lung cancer, esophageal cancer, and thymic cancer. Expertise in targeted therapy, immunotherapy, and management of oncologic emergencies.
Dr. Zhang is Chief Physician and Deputy Director of the First Department of Thoracic Oncology at Hunan Cancer Hospital. Holding a PhD and serving as a master’s supervisor, Dr. Zhang leads one National Natural Science Foundation project and six provincial or municipal projects. Honors include the Hunan Provincial Science and Technology Progress Award (Second Class) and selection for the Hunan High-Level Health Talent 225 Project.
Name order: in Chinese the family name comes first (Zhang Lemeng). Papers usually list the name as Lemeng Zhang or Zhang L.
Selected publications
55 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int Immunopharmacol, 2026 (senior author): Synergistic effects of neutrophil extracellular traps and NF-κB on promoting tumor progression and immune evasion in lung adenocarcinoma. PubMed 41389668
- Mater Today Bio, 2025 (senior author): Enhancing clinical precision in lung cancer tissue biopsy through elevated response-threshold of an endoplasmic reticulum-targeted fluorogenic probe. PubMed 40160246
- Front Oncol, 2025 (senior author): Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib. PubMed 40308505
- Sci Rep, 2025 (senior author): Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis. PubMed 39747391
- World J Clin Cases, 2024 (senior author): Machine learning based on metabolomics unveils neutrophil extracellular trap-related metabolic signatures in non-small cell lung cancer patients undergoing chemoimmunotherapy. PubMed 39015934
- Front Pharmacol, 2024 (senior author): Clinical significance and biological function of interferon regulatory factor 1 in non-small cell lung cancer. PubMed 38915471
- Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2024 (senior author): Research progress on novel antibody drug conjugates in cancer therapy. PubMed 38755726
- BMJ Support Palliat Care, 2024 (first author): Lung cancer distress: screening thermometer meta-analysis. PubMed 35172980
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion